Do you have patients who would benefit from Lilly's Non-Branded Insulins?

Consider Lilly's Portfolio of Non-Branded Insulins for patients who face high out-of-pocket costs^* for their Humalog^®.

^*Note that for many people with commercial drug insurance, Lilly's branded insulins may still have a lower out-of-pocket cost than Lilly's Non-Branded Insulins.^†

^†Out-of-pocket costs may vary depending on a patient’s plan. Please contact plan administrator for most current information.

Actor portrayal. Not an actual patient.

Click here for a bilingual brochure that you can use to provide information about Insulin Lispro to your English and Spanish-speaking patients.

Humalog (insulin lispro, 100 units/mL) and Insulin Lispro Injection (100 units/mL) are indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Humalog Mix75/25 and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are [mixtures of intermediate-acting and rapid-acting human insulin analogs] indicated to improve glycemic control in adults with diabetes mellitus.

Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins in Humalog Mix75/25, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.

These non-branded insulin lispro products are Humalog products.

Same safety and efficacy profile
Same manufacturer
Same KwikPen^® and vial^‡

Continue to write the Humalog-branded product.

Pharmacists can determine the most affordable Lilly insulin option for your patients.^¶

Select Safety Information

Humalog, Insulin Lispro Injection, Humalog Mix75/25, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to these insulins or any of their excipients.

All of Lilly's Non-Branded Insulins are available in a KwikPen, which is a small lightweight, prefilled insulin pen for patients with diabetes who want a portable device.

For proper administration, pharmacists should engage patients and caregivers to discuss the Instructions for Use for these insulins.

Note that for many people with commercial drug insurance, Lilly's branded insulins may still have a lower out-of-pocket cost than Lilly's Non-Branded Insulins.^¶ Pharmacists, please see the information below about “Steps to ensure Humalog patients get the most affordable Lilly insulin option.”

^‡Vials are available only for Lilly’s Insulin Lispro Injection U-100.
^¶Out-of-pocket costs may vary depending on a patient’s plan. Please contact plan administrator for most current information.

Insulin Lispro Injection U-100 Vial (100 units/mL) and KwikPens®

Branded Name	Non-branded Name
Branded Name Humalog^® U-100	Non-branded Name Insulin Lispro Injection U-100
Branded Name Humalog^® Mix75/25^™	Non-branded Name Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen
Branded Name Humalog^® Junior KwikPen^®	Non-branded Name Insulin Lispro Injection Junior KwikPen

How to stock and order

Sales Package Information and Specifications

Sales Package Size	NDC and UPC	Wholesale Acquisition Cost (WAC)*
Sales Package Size INSULIN LISPRO INJECTION KWIKPEN 100 U/ML 3 ML X 5	NDC and UPC NDC: 0002-8222-59 UPC: 3-0002-8222-59-1	Wholesale Acquisition Cost (WAC)^* $159.12^*
Sales Package Size INSULIN LISPRO INJECTION 100 U/ML 10 ML X 1 VIAL	NDC and UPC NDC: 0002-7737-01 UPC: 3-0002-7737-01-0	Wholesale Acquisition Cost (WAC)^* $25.00^*
Sales Package Size INSULIN LISPRO PROTAMINE AND INSULIN LISPRO INJECTABLE SUSPENSION MIX75/25 KWIKPEN	NDC and UPC NDC: 0002-8233-05 UPC: 3-00028-233-05-4	Wholesale Acquisition Cost (WAC)^* $159.12^*
Sales Package Size INSULIN LISPRO INJECTION JUNIOR KWIKPEN 100 U/ML 3 ML X 5	NDC and UPC NDC: 0002-7752-05 UPC: 3-0002-7752-05-1	Wholesale Acquisition Cost (WAC)^* $159.12^*

^*The Lilly WAC is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA, LLC to any entity.

Product	Carton Dimensions (L x W x H) (inches)	Carton Weight (ounces)	Cartons Per Case	Case Dimensions (L x W x H) (inches)	Case Weight (pounds)	Case Per Pallet
Product INSULIN LISPRO INJECTION KWIKPEN 100 U/ML 3 ML X 5	Carton Dimensions (L x W x H) (inches) 3.6 x 1.1 x 5.8	Carton Weight (ounces) 6.72	Cartons Per Case 36	Case Dimensions (L x W x H) (inches) 15.1 x 11.1 x 6.6	Case Weight (pounds) 16.24	Case Per Pallet 77
Product INSULIN LISPRO INJECTION 100 U/ML 10 ML X 1 VIAL	Carton Dimensions (L x W x H) (inches) 1.8 x 1.5 x 2.6	Carton Weight (ounces) 1.25	Cartons Per Case 100	Case Dimensions (L x W x H) (inches) 18.8 x 8.2 x 5.9	Case Weight (pounds) 8.5	Case Per Pallet 70
Product INSULIN LISPRO PROTAMINE AND INSULIN LISPRO INJECTABLE SUSPENSION MIX75/25™ KWIKPEN	Carton Dimensions (L x W x H) (inches) 3.6 x 1.1 x 5.8	Carton Weight (ounces) 6.72	Cartons Per Case 36	Case Dimensions (L x W x H) (inches) 15.1 x 11.1 x 6.6	Case Weight (pounds) 16.24	Case Per Pallet 77
Product INSULIN LISPRO INJECTION JUNIOR KWIKPEN 100 U/ML 3 ML X 5	Carton Dimensions (L x W x H) (inches) 3.6 x 1.1 x 5.8	Carton Weight (ounces) 6.6	Cartons Per Case 36	Case Dimensions (L x W x H) (inches) 15.1 x 11.1 x 6.6	Case Weight (pounds) 16.24	Case Per Pallet 77

Minimum Order Quantity: 1 carton of 5 KwikPens or 100 vials

Billing Quantity: 15 mL per 5-pen pack or 10 mL per vial

Prescription Legend: Yes

Returned Goods: Please visit www.lillytrade.com for further details.

Distribution: Lilly USA Authorized Distributors of Record

Storage: Patients may store Insulin Lispro Injection and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix 75/25 at room temperature (below 86° F [30° C]) up to 10 days. For any questions regarding storage and handling, call 1-800-LillyRx 1-800-545-5979 ).

TAA Compliant: Yes

Country of Origin: USA

Steps to ensure Humalog patients get the most affordable Lilly insulin option:

How to compare out-of-pocket cost (KwikPen example):

Take two substitutable medicines (example: Humalog and Insulin Lispro Injection).
Run the NDC for each – Humalog U-100 KwikPen 0002-8799-59 and Lilly’s Insulin Lispro Injection KwikPen 0002-8222-59.
Dispense the Lilly insulin that offers your patient the lower out-of-pocket cost and inform them if a substitution was made.

The Lilly Diabetes Solution Center may be able to help patients who need additional assistance paying for medications or care. Encourage your patients to call the Lilly Diabetes Solution Center at 1-833-808-1234.

Prescribing Information

Insulin Lispro Injection Prescribing Information

Insulin Lispro Injection Patient Information

Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 Prescribing Information

Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 Patient Information

Instructions for Use

Insulin Lispro Injection Vial

Insulin Lispro Injection KwikPen

Insulin Lispro Injection Junior KwikPen

Insulin Lispro Protamine & Insulin Lispro Injectable Suspension Mix75/25 KwikPen

IMPORTANT SAFETY INFORMATION

Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to these insulins or any of their excipients.

Never share a Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, or Humalog Mix50/50 prefilled pen, cartridge, reusable pen compatible with Lilly 3 mL cartridges, or syringe between patients, even if the needle is changed. Patients using vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Due to reports of hyperglycemia and hypoglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant antidiabetic products may be needed

Hypoglycemia: Severe hypoglycemia may be life threatening and can cause seizures or death. Hypoglycemia is the most common adverse reaction of Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. Monitor blood glucose and increase monitoring frequency with changes to insulin dosage, use with glucose-lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness.

Hypoglycemia Due to Medication Errors: Instruct patients to always check the insulin label before each injection to avoid medication errors. Humalog U-200 should not be transferred from the Humalog KwikPen to a syringe as overdose and severe hypoglycemia can occur.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. If hypersensitivity reactions occur, discontinue the use of insulin and treat per standard of care until signs and symptoms resolve.

Hypokalemia: Hypokalemia may be life threatening. Insulins, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50, cause a shift in potassium from the extracellular to intracellular space possibly leading to hypokalemia, which, if untreated, may result in respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia (e.g., patients using potassium-lowering medications or medications sensitive to serum potassium concentrations).

Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Thiazolidinediones (TZDs), which are PPAR-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. This may lead to or exacerbate heart failure. Observe patients for signs and symptoms of heart failure and consider discontinuation or dose reduction of the PPAR-gamma agonist.

Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction: Malfunction of the insulin pump device, infusion set, or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using subcutaneous insulin infusion pumps must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.

Adverse reactions associated with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 include hypoglycemia, hypokalemia, allergic reactions, injection-site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema.

Some medications may alter glucose metabolism, insulin requirements, and the risk for hypoglycemia or hyperglycemia. Signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs. Particularly close monitoring may be required.

HI BOI SP U100 75/25 HCP ISI 10MAR2023

INDICATIONS

Humalog and Insulin Lispro Injection are indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Humalog Mix75/25, Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are [mixtures of insulin lispro protamine, an intermediate acting human insulin analog, and insulin lispro, a rapid-acting human insulin analog] indicated to improve glycemic control in adults with diabetes mellitus.

Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins in Humalog Mix75/25, Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.